CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
驱动 CAR-T 细胞靶向致癌免疫肽组的路线图
英文原题：A roadmap for driving CAR T cells toward the oncogenic immunopeptidome.
查看英文原题
A roadmap for driving CAR T cells toward the oncogenic immunopeptidome.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞治疗的一项关键障碍是缺乏能够广泛、稳定表达且仅存在于肿瘤中的靶抗原。在一项全面的多组学和临床前研究中，Yarmarkovich等人为开发靶向神经母细胞瘤致癌免疫肽组的肽中心型（PC）CAR提供了概念验证，并证明了其疗效。
展开英文摘要原文
A critical barrier to CAR T cell therapy is the paucity of target antigens that are broadly and stably expressed exclusively in tumors. In their comprehensive multi-omics and pre-clinical study, Yarmarkovich et al. provide proof of principle for the development and efficacy of peptide centric (PC)-CARs targeting the oncogenic immunopeptidome of neuroblastoma.
论文信息
- 作者
- Irving M、Zoete V、Bassani-Sternberg M、Coukos G
- 单位
- Department of Oncology, Ludwig Institute for Cancer Research Lausanne, Lausanne Teaching Hospital and University of Lausanne, Lausanne, Switzerland. Electronic address: melita.irving@unil.ch.Switzerland
- 文献类型
- 评论
- 期刊
- Cancer cell2022 Jan 10
- 原文标识
- PubMed 35016027 · DOI 10.1016/j.ccell.2021.12.011